Liza Marie Rummler

Liza Marie Rummler

Auto-generated profile, based on publicly available information

Liza Marie Rummler

German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
AKAlexander Klimka
Alexander Klimka
SMSonja Mertins
Sonja Mertins
ANAnne Kristin Nicolai
Anne Kristin Nicolai
LMLiza Marie Maus
Liza Marie Maus
PHPaul G. Higgins
Paul G. Higgins
MKMartin Martin Krönke
Martin Martin Krönke
Staphylococcus aureus represents a serious infectious threat to global public health and a vaccine against S. aureus represents an unmet medical need. We here characterise two S. aureus vaccine candidates, coproporphyrinogen III oxidase (CgoX) and triose phosphate isomerase (TPI), which fulfil essential housekeeping functions in heme synthesis and glycolysis, respectively. Immunisation with rCgoX and rTPI elicited protective immunity against S. aureus bacteremia. Two monoclonal antibodies (mAb), CgoX-D3 and TPI-H8, raised against CgoX and TPI, efficiently provided protection against S. aureus infection. MAb-CgoX-D3 recognised a linear epitope spanning 12 amino acids (aa), whereas TPI-H8 recognised a larger discontinuous epitope. The CgoX-D3 epitope conjugated to BSA elicited a strong, protective immune response against S. aureus infection. The CgoX-D3 epitope is highly conserved in clinical S. aureus isolates, indicating its potential wide usability against S. aureus infection. These data suggest that immunofocusing through epitope-based immunisation constitutes a strategy for the development of a S. aureus vaccine with greater efficacy and better safety profile.

12 April 2023 in Journal of Medical Microbiology
Verified
Journal Article
Open access
SMSonja Mertins
Sonja Mertins
PHPaul G. Higgins
Paul G. Higgins
CTCaroline Thunissen
Caroline Thunissen
HMHenri Magein
Henri Magein
QGQuentin Gilleman
Quentin Gilleman
AKAlexander Klimka
Alexander Klimka
Introduction. Acinetobacter baumannii infections can be extremely challenging to treat owing to the worldwide prevalence of multidrug-resistant isolates, especially against carbapenems. Colonization with carbapenem-resistant A. baumannii (CRAb) requires rapid action from an infection control perspective because the organism is known for its propensity for epidemic spread. Hypothesis/Gap Statement. There is an unmet medical need to rapidly identify CRAb to enable appropriate antimicrobial treatment and to prevent transmission. Aim. Our aim was to expand the OXA-detection abilities of the rapid immunochromatographic test (ICT) OXA-23 K-SeT (Coris BioConcept) to include OXA-40- and OXA-58-like carbapenemases, which together confer carbapenem resistance to more than 94 % of CRAb isolates worldwide. Methodology. We used hybridoma technology to generate mAbs against OXA-40 and OXA-58 and selected them for productivity and specificity against recombinant and endogenous OXA-40 and OXA-58. Combinations of the resulting mAbs were analysed in ICT format for their ability to detect recombinant rOXA-40His6 or rOXA-58His6, respectively. Subsequently, selected antibody pairs were implemented into single-OXA-40 or single-OXA-58 prototypes and the final OXA-23/40/58/NDM ICT and were evaluated on clinical Acinetobacter spp. isolates with well-defined carbapenem resistance mechanisms. Results. Five anti-OXA-40 and anti-OXA-58 mAbs were selected. Competition ELISA with combinations of these antibodies revealed that the anti-OXA-40 antibodies bind to one of two binding clusters on OXA-40, while anti-OXA-58 antibodies bind to one of four binding clusters on OXA-58. Direct binding to the corresponding antigen in an ICT format has left only three antibodies against rOXA-40His6 and rOXA-58His6, respectively for the subsequent sandwich ICT selection procedure, which revealed that the anti-OXA-40 (#5) and anti-OXA-58 (#A8) mAbs in combination with the cross-reactive mAb #C8 performed best. They were implemented into single-OXA-40 and single-OXA-58 ICT prototypes and evaluated. These single ICT prototypes demonstrated 100 % specificity and sensitivity. Based on these results, an OXA-23/40/58/NDM-ICT was developed, complemented with OXA-23 and NDM-specific detection. An evaluation with selected carbapenem-resistant Acinetobacter spp. isolates (n=34) showed 100 % specificity. Conclusion. With this easy-to-use detection assay, one can save 12–48 h in diagnostics, which helps to treat patients earlier with appropriate antibiotics and allows immediate intervention to control transmission of CRAb.

17 November 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
LMLiza Marie Maus
Liza Marie Maus
DGDaniela Simone Grumme
Daniela Simone Grumme
AGAlexander Gluschko
Alexander Gluschko
KWKatja Wiegmann
Katja Wiegmann
AKAlexander Klimka
Alexander Klimka
MKMartin Martin Krönke
Martin Martin Krönke
Background: Staphylococcus aureus (S. aureus) remains a major global pathogen causing a wide spectrum of diseases. Human adults harbor circulating antibodies against most staphylococcal antigens, which provide little protection against invasive S. aureus infection. Conventional S. aureus vaccines are poised to predominantly repeat the natural, non-protective antibody responses. Objective: We investigated the immunological feasibility of an epitope-focused vaccine targeting the D3 epitope of coproporphyrinogen III oxidase (CgoX), which is recognized by the protective monoclonal antibody anti-CgoX-D3. Methods: The potential of the D3 epitope to break the dominant but non-protective immunity to CgoX was investigated in laboratory mice. The seroprevalence of antibodies against the D3 epitope was investigated in sera from healthy blood donors and patients with S. aureus bacteremia. Results: All sera from 204 healthy blood donors harbored antibodies against CgoX, whereas only 10.3% contained antibodies against the D3 epitope, indicating its immunological subdominance. In patients with invasive S. aureus infection, D3-specific responses were more frequent but remained at low serum concentrations, confirming the quantitative subdominance of the protective D3 epitope. Prime-boosting experiments in mice with combinations of whole CgoX and a CRM197-CgoX-D3 conjugate (D3-CRM) revealed that mice primed and boosted with whole CgoX developed weak D3-specific responses. Boosting CgoX-primed mice with D3-CRM resulted in the generation of robust titers of high-affinity D3 binding antibodies. Conclusions: The immunization history with CgoX markedly influences subsequent D3-specific antibody responses. Epitope-focused vaccination with D3-CRM can overcome the attenuation associated with prior CgoX immunization and elicit high-affinity D3-specific antibodies.